Digest Network Come funziona
Network
/
Società
Io
Non verificato

Ionis Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaCardiologiaFarmaceuticaMedicina - VarieSalute

79 comunicati stampa

Guarda tutti i comunicati
04/09/2026
Industria
Farmaceutica
Salute
Medicina - Varie
Cardiologia
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
03/09/2026
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
03/09/2026
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Ionis to present at upcoming investor conferences
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
20/08/2026
Web e Social Network
Fiere
Eventi
Salute
Medicina - Varie
Scienza
Farmaceutica
Cardiologia
Biotecnologia
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
29/07/2026
Mercato del lavoro
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
29/07/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Salute
Biotecnologia
Farmaceutica
Cardiologia
Ionis reports second quarter 2026 financial results and highlights progress on key programs
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
15/07/2026
Salute
Biotecnologia
Farmaceutica
Cardiologia
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Ionis to hold second quarter 2026 financial results webcast
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
14/07/2026
Eventi
Industria
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
13/07/2026
Farmaceutica
Salute
Medicina - Varie
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
09/07/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Cardiologia
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0